Manreet Basra, MD
Cardiovascular Disease (Cardiology) · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
- Since medical school
- 16 years
- Graduated 2010
Offices
7 locations · Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
Hospitals listed: Adventist Health Lodi Memorial · Dameron Hospital · Mark Twain Medical Center · St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Basra’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C137215 · Current
Licensed to practise in California · since 2015 · expires 2027-01-31 · Baba Farid University of Health Sciences, Sri Guru Ram Das Institute of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas P9302Physician License · since 2014 · expires 2016-05-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiology
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Lodi MemorialLodi, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.222, Oct 2024 – Sep 2025
- Dameron HospitalStockton, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — MRSA Bacteremia: 18.373, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Mark Twain Medical CenterSan Andreas, CACritical Access Hospital · Voluntary non-profit - Other · No emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsNo measure marked better or worse than the national rate
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Lodi Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.222 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.22) · 678 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.59 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.28 (143.15 to 263.4) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 334 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 570 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,823 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 4,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 4,094 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.83 to 5.53) · 476 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.8 to 4.13) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.29 (0 to 17.86) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 142 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.53) · 3,347 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.368 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.655 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.506 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 47.3 · 381 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.2 · 604 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 661 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.6 (8.9 to 15.2) · 932 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 449 cases | No different | Jan 2024 – Dec 2024 |
What patients said (438 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Dameron Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 8 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 18.373 | Worse | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.46 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.1 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 41 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,121 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.52) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.06 (0.59 to 5.54) · 371 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 116 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.41 (0.76 to 4.05) · 363 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.35 (0.5 to 18.2) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.94 (0.72 to 9.16) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 74 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.37) · 1,066 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.678 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 118 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 144 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 41.3 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.5 · 89 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 178 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 44 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 78 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.6 to 17.2) · 386 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.5) · 261 cases | No different | Jan 2024 – Dec 2024 |
What patients said (385 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 72% |
| Doctors "always" explained things so they could understand | 62% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 74% |
| Patients who gave a rating of "9" or "10" (high) | 55% |
| Staff "always" explained new medications | 61% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Mark Twain Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 9.3 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.9 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 353 cases | None | Jul 2024 – Jun 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 81.9 · 54 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33.7 · 108 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4 to 9.3) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (7.3 to 14.2) · 54 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.4) · 375 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.7 to 1.5) · 89 cases | No different | Jan 2024 – Dec 2024 |
What patients said (151 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 89% |
| Nurses "always" communicated well | 90% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 85% |
| Nurses "always" listened carefully | 91% |
| Nurses "always" treated them with courtesy and respect | 93% |
| "Always" quiet at night | 65% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 60% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$316,984
Medicare paid this office $316,984 for 1,612 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 555 | $94,014 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 181 | $27,768 | $153 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $24,945 | $378 |
| Ultrasound of both sides of head and neck blood flow | 148 | $24,254 | $163 |
| Critical care, first 30-74 minutes | 66 | $21,496 | $171 |
See all 35 services
| Return visit (30+ min) | 555 | $94,014 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 181 | $27,768 | $153 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $24,945 | $378 |
| Ultrasound of both sides of head and neck blood flow | 148 | $24,254 | $163 |
| Critical care, first 30-74 minutes | 66 | $21,496 | $171 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 309 | $17,134 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $14,146 | $97 |
| New patient visit (45+ min) | 86 | $10,339 | $120 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 66 | $10,060 | $76 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 36 | $6,787 | $183 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 813 | $6,262 | $6 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,498 | $104 |
| Long return visit (40+ min) | 29 | $4,938 | $150 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 78 | $4,383 | $55 |
| Programming of dual lead pacemaker system | 44 | $4,069 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 39 | $3,418 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $3,339 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 241 | $2,887 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 409 | $2,582 | $5 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 14 | $2,161 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,160 | $144 |
| Ultrasound of leg arteries at rest and after exercise | 14 | $1,844 | $132 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 27 | $1,616 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 43 | $1,476 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 33 | $1,414 | $22 |
| Injection, regadenoson, 0.1 mg | 50 | $1,111 | None |
| Programming of single lead pacemaker system | 13 | $1,045 | $55 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 12 | $693 | $58 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 23 | $509 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 34 | $500 | $15 |
| Ultrasound of heart, follow-up | 17 | $329 | $19 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 17 | $264 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $151 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 18 | $108 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $87 | $3 |
Who their Medicare patients are
1,612 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 19% · Women 58% · Also on Medicaid 38% · Health risk score 1.89. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 42% · Chronic kidney disease 38% · Coronary heart disease 37% · Heart failure 34% · Atrial fibrillation 33% · COPD 26% · Depression 25% · Stroke 17% · Cancer 15% · Dementia 12%.
The office billed $1,055,766, Medicare allowed $418,901 and paid $316,984; for 5,119 services of 58 kinds; $1,111 of it was for drugs given in the office and $315,872 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,612 | 5,119 | 75 | 1.89 | $1,055,766 | $316,984 |
| 2023 | 845 | 3,503 | 76 | 1.75 | $850,711 | $268,390 |
| 2022 | 657 | 2,828 | 75 | 1.66 | $728,482 | $220,084 |
| 2021 | 656 | 3,138 | 74 | 1.68 | $1,033,259 | $262,060 |
| 2020 | 543 | 2,518 | 73 | 1.87 | $819,250 | $194,283 |
| 2019 | 685 | 3,738 | 73 | 1.92 | $1,191,852 | $297,109 |
| 2018 | 669 | 3,172 | 73 | 1.73 | $954,100 | $236,469 |
| 2017 | 746 | 2,647 | 73 | 1.74 | $465,869 | $133,742 |
| 2016 | 722 | 2,239 | 73 | 1.65 | $596,309 | $143,700 |
| 2015 | 117 | 258 | 71 | 1.49 | $93,003 | $22,293 |
| 2014 | 484 | 596 | 70 | 2.21 | $47,957 | $15,757 |
| 2013 | 131 | 152 | 68 | 2.17 | $16,598 | $7,135 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 30 services
| Return visit (30+ min) | 480 | $76,201 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | $35,104 | $151 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 72 | $26,516 | $368 |
| Ultrasound of both sides of head and neck blood flow | 128 | $20,110 | $157 |
| Critical care, first 30-74 minutes | 56 | $15,153 | $168 |
| New patient visit (45+ min) | 87 | $11,042 | $127 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 72 | $10,975 | $76 |
| Injection, regadenoson, 0.1 mg | 52 | $9,234 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 154 | $8,693 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $8,343 | $95 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 461 | $6,439 | $11 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 28 | $4,957 | $177 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 80 | $4,177 | $52 |
| Ultrasound of heart with probe in esophagus, with report | 44 | $3,902 | $85 |
| Long return visit (40+ min) | 24 | $3,235 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,823 | $101 |
| Programming of dual lead pacemaker system | 33 | $2,527 | $57 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 32 | $1,768 | $55 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 28 | $1,022 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 35 | $976 | $17 |
| Anticoagulant management of patient taking warfarin | 14 | $738 | $9 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $670 | $61 |
| Ultrasound of heart blood flow, valves and chambers | 43 | $639 | $14 |
| Ultrasound of heart, follow-up | 21 | $417 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $263 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 28 | $188 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $186 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 33 | $175 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $123 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 44 | $114 | $2 |
2022: 29 services
| Return visit (30+ min) | 445 | $67,621 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 190 | $30,095 | $157 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 60 | $23,096 | $379 |
| Ultrasound of both sides of head and neck blood flow | 134 | $21,300 | $158 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 61 | $10,705 | $87 |
| New patient visit (45+ min) | 71 | $8,787 | $124 |
| Injection, regadenoson, 0.1 mg | 45 | $8,730 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 368 | $4,753 | $10 |
| Ultrasound of heart with probe in esophagus, with report | 47 | $4,571 | $88 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 69 | $3,762 | $53 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 17 | $3,292 | $183 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 54 | $3,077 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $2,805 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,079 | $160 |
| Programming of dual lead pacemaker system | 30 | $2,033 | $52 |
| Long return visit (40+ min) | 13 | $1,921 | $137 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 12 | $1,853 | $154 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,727 | $102 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $1,363 | $52 |
| Short return visit (20+ min) | 18 | $1,266 | $70 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $818 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $758 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 37 | $599 | $15 |
| Ultrasound of heart, follow-up | 17 | $348 | $20 |
| Anticoagulant management of patient taking warfarin | 12 | $277 | $9 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $140 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 34 | $102 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 20 | $100 | $5 |
| Infusion, normal saline solution, 250 cc | 41 | $22 | None |
2021: 25 services
| Return visit (30+ min) | 469 | $81,006 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 259 | $44,805 | $170 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 79 | $32,140 | $407 |
| Ultrasound of both sides of head and neck blood flow | 86 | $14,339 | $167 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 79 | $13,688 | $89 |
| New patient visit (45+ min) | 100 | $13,169 | $132 |
| Injection, regadenoson, 0.1 mg | 55 | $10,467 | None |
| Ultrasound of heart with probe in esophagus, with report | 52 | $6,071 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 384 | $5,344 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 91 | $4,980 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $4,455 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 60 | $3,360 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,606 | $163 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 16 | $2,532 | $158 |
| Ultrasound of leg arteries at rest and after exercise | 17 | $2,397 | $133 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 36 | $2,145 | $60 |
| Programming of dual lead pacemaker system | 26 | $2,132 | $59 |
| Short return visit (20+ min) | 14 | $947 | $68 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 28 | $875 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 43 | $791 | $15 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 21 | $725 | $23 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $290 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 44 | $153 | $3 |
| Infusion, normal saline solution, 250 cc | 79 | $44 | None |
| Injection, aminophyllin, up to 250 mg | 20 | $40 | None |
2020: 27 services
| Return visit (30+ min) | 379 | $55,185 | $77 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 75 | $30,034 | $400 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 157 | $27,462 | $164 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 75 | $13,404 | $90 |
| Injection, regadenoson, 0.1 mg | 57 | $10,755 | None |
| Ultrasound of both sides of head and neck blood flow | 44 | $7,159 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $6,106 | $87 |
| New patient visit (45+ min) | 50 | $5,897 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 66 | $4,419 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 80 | $4,394 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,155 | $166 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 257 | $3,418 | $12 |
| Ultrasound of heart with probe in esophagus, with report | 23 | $2,751 | $92 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 14 | $2,387 | $159 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,433 | $68 |
| Programming of dual lead pacemaker system | 16 | $1,361 | $57 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,292 | $68 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $937 | $62 |
| Injection of additional new drug or substance into vein | 19 | $830 | $14 |
| Injection of drug or substance into vein | 19 | $647 | $34 |
| Short return visit (20+ min) | 16 | $620 | $39 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $495 | $38 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $425 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 17 | $344 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $175 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $77 | $3 |
| Infusion, normal saline solution, 250 cc | 73 | $37 | None |
2019: 30 services
| Return visit (30+ min) | 445 | $79,206 | $79 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 269 | $48,274 | $171 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 83 | $33,918 | $409 |
| Ultrasound of both sides of head and neck blood flow | 186 | $32,561 | $167 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 84 | $14,698 | $88 |
| New patient visit (45+ min) | 92 | $11,028 | $120 |
| Injection, regadenoson, 0.1 mg | 58 | $10,604 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $8,301 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 437 | $8,032 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 86 | $5,016 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 93 | $4,902 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,228 | $108 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 26 | $4,133 | $159 |
| Ultrasound of leg arteries or artery grafts | 14 | $3,028 | $216 |
| Ultrasound of leg arteries at rest and after exercise | 19 | $2,767 | $138 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 18 | $2,660 | $148 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,624 | $90 |
| Short return visit (20+ min) | 35 | $2,155 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 30 | $2,058 | $69 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $2,003 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,977 | $165 |
| Programming of dual lead pacemaker system | 15 | $1,185 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $888 | $59 |
| Limited ultrasound scan behind abdominal cavity | 17 | $835 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 27 | $495 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $426 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 29 | $344 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 17 | $171 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $96 | $3 |
| Infusion, normal saline solution, 250 cc | 84 | $41 | None |
2018: 24 services
| Return visit (30+ min) | 394 | $61,175 | $73 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 302 | $41,222 | $132 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 105 | $29,945 | $285 |
| Ultrasound of both sides of head and neck blood flow | 155 | $22,037 | $139 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 67 | $11,672 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $10,712 | $84 |
| New patient visit (45+ min) | 90 | $9,917 | $110 |
| Injection, regadenoson, 0.1 mg | 44 | $7,802 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 321 | $5,023 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 41 | $4,696 | $109 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 75 | $4,442 | $57 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 75 | $3,980 | $53 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 20 | $2,936 | $147 |
| Ultrasound of leg arteries at rest and after exercise | 27 | $2,747 | $102 |
| Ultrasound of leg arteries or artery grafts | 14 | $2,551 | $182 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,709 | $71 |
| Short return visit (20+ min) | 31 | $1,323 | $41 |
| Programming of dual lead pacemaker system | 14 | $772 | $34 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 44 | $644 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 136 | $639 | $4 |
| Ultrasound study of arm and leg arteries | 16 | $617 | $39 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 11 | $547 | $25 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 44 | $471 | $11 |
| Infusion, normal saline solution, 250 cc | 67 | $33 | None |
2017: 17 services
| Return visit (30+ min) | 363 | $38,591 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 342 | $26,379 | $76 |
| New patient visit (45+ min) | 182 | $17,771 | $98 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $10,999 | $85 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 111 | $6,921 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 41 | $5,425 | $109 |
| Short return visit (20+ min) | 99 | $3,994 | $39 |
| Ultrasound of both sides of head and neck blood flow | 59 | $3,658 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 59 | $2,927 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 123 | $2,181 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 289 | $2,128 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 132 | $2,074 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 123 | $1,470 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 16 | $1,213 | $71 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $523 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 24 | $506 | $21 |
| Programming of dual lead pacemaker system | 11 | $415 | $28 |
2016: 18 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 357 | $39,538 | $110 |
| Return visit (30+ min) | 307 | $33,570 | $65 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 102 | $16,510 | $162 |
| New patient visit (45+ min) | 91 | $9,422 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,893 | $82 |
| New patient visit (60+ min) | 41 | $5,227 | $127 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 30 | $5,227 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,215 | $106 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $3,570 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 179 | $2,469 | $13 |
| Injection, regadenoson, 0.1 mg | 12 | $2,034 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 30 | $1,659 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 201 | $1,479 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 78 | $1,439 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 78 | $938 | $12 |
| Short return visit (20+ min) | 23 | $840 | $31 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 11 | $239 | $22 |
| Infusion, normal saline solution, 250 cc | 30 | $11 | None |
2015: 4 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $7,297 | $187 |
| Return visit (30+ min) | 40 | $3,514 | $86 |
| Short return visit (20+ min) | 22 | $1,380 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 61 | $861 | $14 |
2014: 7 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 73 | $3,608 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 326 | $2,325 | $6 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,047 | $102 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 13 | $1,661 | $128 |
| Return visit (30+ min) | 19 | $1,082 | $54 |
| Short return visit (20+ min) | 18 | $687 | $33 |
| Ultrasound of heart | 15 | $527 | $35 |
2013: 5 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,822 | $101 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 26 | $1,230 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,223 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $902 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 40 | $309 | $6 |
Medicaid work
$55,409 in 2024
Medicaid paid $55,409 for 2,141 billed services this clinician did in 2024, up to 160 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 251 | $22,286 |
| Return visit (30+ min) | 416 | $14,580 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,220 | $14,037 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 130 | $3,021 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 124 | $1,485 |
| 2024 | 2,141 | 5 | 160 | $55,409 |
| 2023 | 1,202 | 4 | 49 | $65,516 |
| 2022 | 1,025 | 4 | 62 | $66,924 |
| 2021 | 1,944 | 8 | 101 | $160,032 |
| 2020 | 1,840 | 8 | 99 | $152,103 |
| 2019 | 2,818 | 11 | 111 | $250,804 |
| 2018 | 2,823 | 15 | 82 | $222,945 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 243 | $35,723 |
| Return visit (30+ min) | 589 | $19,746 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 358 | $8,814 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 12 | $1,233 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 169 | $36,492 |
| Return visit (30+ min) | 515 | $20,864 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 329 | $9,568 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 12 | $0 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 410 | $77,701 |
| Return visit (30+ min) | 885 | $39,313 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 43 | $14,221 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 444 | $13,478 |
| CARDIOVASCULAR STRESS TEST | 89 | $9,118 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $4,627 |
| New patient visit (45+ min) | 17 | $1,447 |
| Infusion, normal saline solution, 250 cc | 28 | $127 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 327 | $71,960 |
| Return visit (30+ min) | 858 | $36,512 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 419 | $13,821 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 54 | $13,265 |
| CARDIOVASCULAR STRESS TEST | 87 | $8,687 |
| New patient visit (45+ min) | 71 | $6,786 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $1,045 |
| Infusion, normal saline solution, 250 cc | 12 | $27 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 481 | $101,239 |
| Return visit (30+ min) | 1,000 | $42,328 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 114 | $29,081 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 150 | $25,777 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 751 | $22,730 |
| CARDIOVASCULAR STRESS TEST | 131 | $12,437 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 54 | $9,557 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 48 | $5,719 |
| New patient visit (45+ min) | 13 | $1,038 |
| Short return visit (20+ min) | 24 | $662 |
| Infusion, normal saline solution, 250 cc | 52 | $234 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 544 | $84,394 |
| Return visit (30+ min) | 916 | $51,531 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 121 | $26,851 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 426 | $14,047 |
| CARDIOVASCULAR STRESS TEST | 103 | $11,257 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 88 | $10,647 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 68 | $8,667 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 37 | $7,448 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 220 | $3,215 |
| CARDIOVASCULAR STRESS TEST | 100 | $2,469 |
| CARDIOVASCULAR STRESS TEST | 100 | $1,858 |
| Short return visit (20+ min) | 13 | $396 |
Drugs they prescribed that Part D paid
$931,494
Pharmacies billed $931,494 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,227) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,347 generic and 880 brand-name prescriptions · $931,494 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 416 | $437,341 | $1,051 |
| Xarelto | 198 | $212,275 | $1,072 |
| Entresto | 77 | $95,231 | $1,237 |
| Jardiance | 81 | $80,581 | $995 |
| Multaq | 19 | $29,212 | $1,537 |
See all 36 drugs
| Eliquis | 416 | $437,341 | $1,051 |
| Xarelto | 198 | $212,275 | $1,072 |
| Entresto | 77 | $95,231 | $1,237 |
| Jardiance | 81 | $80,581 | $995 |
| Multaq | 19 | $29,212 | $1,537 |
| Praluent | 18 | $11,619 | $645 |
| Metoprolol | 340 | $5,168 | $15 |
| Carvedilol | 394 | $3,783 | $10 |
| Losartan | 424 | $3,781 | $9 |
| Atorvastatin | 325 | $3,281 | $10 |
| Rosuvastatin | 194 | $2,758 | $14 |
| Amiodarone | 53 | $1,830 | $35 |
| Flecainide Acetate | 26 | $1,385 | $53 |
| Spironolactone | 154 | $1,383 | $9 |
| Clopidogrel | 103 | $1,137 | $11 |
| Amlodipine Besylate | 228 | $1,068 | $5 |
| Furosemide | 206 | $1,048 | $5 |
| Digoxin | 38 | $820 | $22 |
| Isosorbide Mononitrate Er | 61 | $759 | $12 |
| Lisinopril | 142 | $722 | $5 |
| Metoprolol | 79 | $629 | $8 |
| Hydralazine | 40 | $535 | $13 |
| Warfarin | 68 | $455 | $7 |
| Pravastatin | 24 | $378 | $16 |
| Ezetimibe | 16 | $376 | $23 |
| Diltiazem 24hr Er (Cd) | 25 | $356 | $14 |
| Chlorthalidone | 23 | $329 | $14 |
| Potassium Chloride | 14 | $300 | $21 |
| Simvastatin | 36 | $250 | $7 |
| Hydrochlorothiazide | 81 | $233 | $3 |
| Benazepril | 16 | $218 | $14 |
| Irbesartan | 13 | $214 | $16 |
| Nitroglycerin | 18 | $172 | $10 |
| Triamterene-Hydrochlorothiazid | 15 | $168 | $11 |
| Atenolol | 35 | $148 | $4 |
| Gemfibrozil | 11 | $121 | $11 |
Year by year
| 2024 | 4,227 | 753 | 0% (0) | 21% | $931,494 |
| 2023 | 4,374 | 809 | 0% (0) | 20% | $995,165 |
| 2022 | 4,722 | 756 | 0% (0) | 18% | $756,096 |
| 2021 | 3,318 | 601 | 0% (0) | None | $466,173 |
| 2020 | 1,934 | 301 | 0% (0) | 21% | $234,166 |
| 2019 | 2,073 | 316 | 0% (0) | 17% | $187,550 |
| 2018 | 1,628 | 250 | 0% (0) | 20% | $153,466 |
| 2017 | 1,278 | 196 | 0% (0) | 24% | $103,489 |
| 2016 | 1,005 | 148 | None | 25% | $53,825 |
| 2015 | 92 | 31 | 0% (0) | 12% | $4,707 |
| 2014 | 203 | 29 | 0% (0) | None | $4,612 |
| 2013 | 45 | 20 | 0% (0) | 29% | $2,507 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Eliquis | 397 | $453,333 | $1,142 |
| Xarelto | 218 | $227,566 | $1,044 |
| Entresto | 110 | $160,293 | $1,457 |
| Jardiance | 29 | $42,213 | $1,456 |
| Praluent | 22 | $15,023 | $683 |
| Atorvastatin | 401 | $7,870 | $20 |
| Metoprolol | 393 | $7,327 | $19 |
| Losartan | 407 | $6,925 | $17 |
| Carvedilol | 398 | $5,542 | $14 |
| Rosuvastatin | 199 | $4,880 | $25 |
| Amlodipine Besylate | 262 | $2,932 | $11 |
| Flecainide Acetate | 38 | $2,793 | $73 |
| Clopidogrel | 128 | $2,475 | $19 |
| Lisinopril | 162 | $1,953 | $12 |
| Diltiazem 24hr Er (Cd) | 44 | $1,805 | $41 |
| Metoprolol | 133 | $1,549 | $12 |
| Isosorbide Mononitrate Er | 67 | $1,493 | $22 |
| Furosemide | 218 | $1,466 | $7 |
| Spironolactone | 99 | $1,142 | $12 |
| Chlorthalidone | 30 | $986 | $33 |
| Warfarin | 72 | $873 | $12 |
| Bumetanide | 13 | $780 | $60 |
| Digoxin | 29 | $766 | $26 |
| Hydralazine | 46 | $698 | $15 |
| Gemfibrozil | 12 | $579 | $48 |
| Amlodipine Besylate-Benazepril | 13 | $576 | $44 |
| Amiodarone | 31 | $574 | $19 |
| Pravastatin | 37 | $534 | $14 |
| Simvastatin | 34 | $358 | $11 |
| Hydrochlorothiazide | 44 | $309 | $7 |
| Irbesartan | 14 | $276 | $20 |
| Benazepril | 14 | $263 | $19 |
| Triamterene-Hydrochlorothiazid | 16 | $261 | $16 |
| Potassium Chloride | 13 | $185 | $14 |
| Atenolol | 34 | $137 | $4 |
2022: 36 drugs
| Eliquis | 353 | $308,742 | $875 |
| Xarelto | 297 | $257,660 | $868 |
| Entresto | 70 | $88,302 | $1,261 |
| Brilinta | 14 | $16,480 | $1,177 |
| Praluent | 13 | $6,453 | $496 |
| Metoprolol | 422 | $6,430 | $15 |
| Atorvastatin | 437 | $5,227 | $12 |
| Rosuvastatin | 187 | $4,182 | $22 |
| Losartan | 402 | $3,958 | $10 |
| Flecainide Acetate | 46 | $3,953 | $86 |
| Carvedilol | 440 | $3,466 | $8 |
| Bumetanide | 28 | $2,690 | $96 |
| Clopidogrel | 200 | $2,548 | $13 |
| Diltiazem 24hr Er (Cd) | 76 | $2,373 | $31 |
| Lisinopril | 168 | $1,516 | $9 |
| Isosorbide Mononitrate Er | 96 | $1,509 | $16 |
| Amlodipine Besylate | 293 | $1,497 | $5 |
| Digoxin | 24 | $1,100 | $46 |
| Metoprolol | 141 | $1,098 | $8 |
| Spironolactone | 126 | $1,074 | $9 |
| Furosemide | 248 | $945 | $4 |
| Hydralazine | 63 | $929 | $15 |
| Chlorthalidone | 29 | $800 | $28 |
| Potassium Chloride | 29 | $558 | $19 |
| Valsartan | 21 | $545 | $26 |
| Ezetimibe | 11 | $533 | $48 |
| Pravastatin | 30 | $406 | $14 |
| Verapamil Er | 13 | $380 | $29 |
| Benazepril | 25 | $349 | $14 |
| Warfarin | 47 | $322 | $7 |
| Simvastatin | 44 | $286 | $7 |
| Amiodarone | 28 | $285 | $10 |
| Hydrochlorothiazide | 67 | $283 | $4 |
| Losartan-Hydrochlorothiazide | 23 | $208 | $9 |
| Triamterene-Hydrochlorothiazid | 21 | $131 | $6 |
| Atenolol | 35 | $72 | $2 |
2021: 36 drugs
| Eliquis | 243 | $169,242 | $696 |
| Xarelto | 202 | $154,747 | $766 |
| Entresto | 28 | $36,444 | $1,302 |
| Multaq | 20 | $17,331 | $867 |
| Brilinta | 24 | $14,400 | $600 |
| Pradaxa | 15 | $12,980 | $865 |
| Repatha Sureclick | 14 | $8,635 | $617 |
| Metoprolol | 270 | $5,410 | $20 |
| Atorvastatin | 354 | $4,217 | $12 |
| Losartan | 298 | $3,667 | $12 |
| Rosuvastatin | 119 | $3,110 | $26 |
| Carvedilol | 285 | $2,952 | $10 |
| Flecainide Acetate | 32 | $2,944 | $92 |
| Enoxaparin | 11 | $2,409 | $219 |
| Isosorbide Mononitrate Er | 72 | $1,384 | $19 |
| Clopidogrel | 114 | $1,288 | $11 |
| Amlodipine Besylate | 204 | $1,183 | $6 |
| Ezetimibe | 16 | $1,181 | $74 |
| Valsartan | 17 | $1,052 | $62 |
| Lisinopril | 122 | $962 | $8 |
| Chlorthalidone | 31 | $915 | $30 |
| Metoprolol | 113 | $824 | $7 |
| Spironolactone | 88 | $814 | $9 |
| Diltiazem 24hr Er (Cd) | 37 | $637 | $17 |
| Furosemide | 148 | $609 | $4 |
| Amiodarone | 16 | $567 | $35 |
| Warfarin | 40 | $509 | $13 |
| Losartan-Hydrochlorothiazide | 17 | $427 | $25 |
| Hydralazine | 37 | $376 | $10 |
| Pravastatin | 20 | $356 | $18 |
| Potassium Chloride | 18 | $298 | $17 |
| Benazepril | 21 | $236 | $11 |
| Verapamil Er | 12 | $227 | $19 |
| Hydrochlorothiazide | 49 | $198 | $4 |
| Simvastatin | 21 | $171 | $8 |
| Atenolol | 19 | $47 | $2 |
2020: 25 drugs
| Xarelto | 179 | $116,976 | $653 |
| Eliquis | 75 | $49,654 | $662 |
| Entresto | 12 | $17,021 | $1,418 |
| Brilinta | 12 | $5,745 | $479 |
| Metoprolol | 124 | $2,699 | $22 |
| Losartan | 240 | $2,561 | $11 |
| Vascepa | 14 | $2,360 | $169 |
| Atorvastatin | 203 | $2,113 | $10 |
| Flecainide Acetate | 18 | $1,997 | $111 |
| Rosuvastatin | 27 | $1,432 | $53 |
| Carvedilol | 142 | $1,341 | $9 |
| Isosorbide Mononitrate Er | 62 | $1,078 | $17 |
| Lisinopril | 87 | $739 | $8 |
| Metoprolol | 126 | $690 | $5 |
| Chlorthalidone | 16 | $638 | $40 |
| Furosemide | 109 | $609 | $6 |
| Amlodipine Besylate | 115 | $569 | $5 |
| Warfarin | 37 | $514 | $14 |
| Clopidogrel | 49 | $502 | $10 |
| Amiodarone | 21 | $364 | $17 |
| Spironolactone | 30 | $251 | $8 |
| Fenofibrate | 14 | $230 | $16 |
| Hydrochlorothiazide | 25 | $101 | $4 |
| Benazepril | 15 | $66 | $4 |
| Atenolol | 11 | $30 | $3 |
2019: 27 drugs
| Xarelto | 167 | $97,736 | $585 |
| Eliquis | 64 | $36,720 | $574 |
| Entresto | 22 | $10,302 | $468 |
| Metoprolol | 133 | $3,325 | $25 |
| Atorvastatin | 284 | $2,910 | $10 |
| Rosuvastatin | 47 | $2,129 | $45 |
| Losartan | 221 | $1,854 | $8 |
| Carvedilol | 157 | $1,347 | $9 |
| Isosorbide Mononitrate Er | 69 | $1,218 | $18 |
| Amiodarone | 36 | $945 | $26 |
| Lisinopril | 112 | $803 | $7 |
| Metoprolol | 116 | $744 | $6 |
| Amlodipine Besylate | 129 | $736 | $6 |
| Flecainide Acetate | 16 | $687 | $43 |
| Gemfibrozil | 24 | $623 | $26 |
| Fenofibrate | 19 | $609 | $32 |
| Furosemide | 101 | $465 | $5 |
| Warfarin | 41 | $396 | $10 |
| Clopidogrel | 52 | $389 | $7 |
| Diltiazem 24hr Er (Cd) | 12 | $384 | $32 |
| Chlorthalidone | 20 | $366 | $18 |
| Simvastatin | 12 | $236 | $20 |
| Hydralazine | 14 | $138 | $10 |
| Spironolactone | 12 | $127 | $11 |
| Benazepril | 12 | $109 | $9 |
| Atenolol | 17 | $97 | $6 |
| Hydrochlorothiazide | 22 | $43 | $2 |
2018: 20 drugs
| Xarelto | 178 | $97,602 | $548 |
| Eliquis | 28 | $15,314 | $547 |
| Multaq | 18 | $11,280 | $627 |
| Metoprolol | 136 | $4,383 | $32 |
| Atorvastatin | 179 | $1,817 | $10 |
| Rosuvastatin | 42 | $1,512 | $36 |
| Isosorbide Mononitrate Er | 77 | $997 | $13 |
| Carvedilol | 125 | $801 | $6 |
| Losartan | 160 | $801 | $5 |
| Flecainide Acetate | 13 | $536 | $41 |
| Metoprolol | 101 | $534 | $5 |
| Lisinopril | 85 | $519 | $6 |
| Furosemide | 115 | $475 | $4 |
| Amlodipine Besylate | 89 | $449 | $5 |
| Warfarin | 39 | $406 | $10 |
| Cartia Xt | 11 | $277 | $25 |
| Clopidogrel | 40 | $207 | $5 |
| Diltiazem 24hr Er (Cd) | 12 | $205 | $17 |
| Hydrochlorothiazide | 19 | $86 | $5 |
| Spironolactone | 12 | $71 | $6 |
2017: 19 drugs
| Xarelto | 138 | $71,132 | $515 |
| Metoprolol | 119 | $3,019 | $25 |
| Atorvastatin | 101 | $940 | $9 |
| Metoprolol | 112 | $702 | $6 |
| Rosuvastatin | 28 | $669 | $24 |
| Carvedilol | 110 | $610 | $6 |
| Isosorbide Mononitrate Er | 46 | $495 | $11 |
| Warfarin | 43 | $484 | $11 |
| Amlodipine Besylate | 80 | $338 | $4 |
| Losartan | 79 | $313 | $4 |
| Lisinopril | 64 | $288 | $4 |
| Clopidogrel | 40 | $276 | $7 |
| Diltiazem 24hr Er | 13 | $245 | $19 |
| Furosemide | 75 | $228 | $3 |
| Cartia Xt | 11 | $199 | $18 |
| Simvastatin | 24 | $87 | $4 |
| Benazepril | 15 | $85 | $6 |
| Atenolol | 21 | $78 | $4 |
| Hydrochlorothiazide | 17 | $46 | $3 |
2016: 21 drugs
| Xarelto | 60 | $22,375 | $373 |
| Crestor | 31 | $9,781 | $316 |
| Multaq | 11 | $6,099 | $554 |
| Metoprolol | 89 | $2,189 | $25 |
| Rosuvastatin | 18 | $1,111 | $62 |
| Flecainide Acetate | 12 | $661 | $55 |
| Atorvastatin | 53 | $500 | $9 |
| Metoprolol | 84 | $478 | $6 |
| Clopidogrel | 43 | $454 | $11 |
| Carvedilol | 65 | $386 | $6 |
| Amlodipine Besylate | 78 | $326 | $4 |
| Lisinopril | 58 | $321 | $6 |
| Furosemide | 75 | $283 | $4 |
| Potassium Chloride | 15 | $259 | $17 |
| Isosorbide Mononitrate Er | 28 | $247 | $9 |
| Warfarin | 30 | $246 | $8 |
| Cartia Xt | 12 | $217 | $18 |
| Losartan | 51 | $201 | $4 |
| Atenolol | 28 | $140 | $5 |
| Simvastatin | 24 | $128 | $5 |
| Irbesartan | 12 | $101 | $8 |
2015: 2 drugs
| Metoprolol | 17 | $399 | $23 |
| Atorvastatin | 15 | $342 | $23 |
2014: 5 drugs
| Atorvastatin | 36 | $864 | $24 |
| Metoprolol | 33 | $630 | $19 |
| Clopidogrel | 14 | $330 | $24 |
| Lisinopril | 34 | $132 | $4 |
| Furosemide | 13 | $39 | $3 |
Money from drug and device companies
$652 in 2025
| 2025 | 6 | 21 | None | $652 |
| 2024 | 13 | 27 | None | $657 |
| 2023 | 20 | 67 | None | $2,573 |
| 2022 | 15 | 56 | None | $1,080 |
| 2021 | 12 | 34 | None | $668 |
| 2020 | 8 | 13 | None | $237 |
| 2019 | 16 | 58 | None | $1,573 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Watchman Flx | $214 | 13 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $190 | 2 payments
|
| Abbvie | Rinvoq | $120 | 1 payment
|
| Philips North America | Ambulatory Monitoring & Diagnostics Undivided | $82 | 3 payments
|
| Novartis Pharmaceuticals | Leqvio | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $20 | 1 payment
|
See all 21 published payments
| Boston Scientific | Meals · 2025-12-18 | Watchman Access System | $13 |
| Medtronic | Meals · 2025-12-16 | Symplicity G3 | $15 |
| Boston Scientific | Meals · 2025-12-04 | Farapulse | $5 |
| Boston Scientific | Meals · 2025-11-13 | Watchman Flx | $7 |
| Boston Scientific | Meals · 2025-11-13 | Watchman Flx | $43 |
| Boston Scientific | Meals · 2025-10-15 | Watchman Flx | $33 |
| Novartis Pharmaceuticals | Meals · 2025-09-24 | Leqvio | $25 |
| Boston Scientific | Meals · 2025-09-18 | Watchman Flx | $11 |
| Medtronic | Meals · 2025-09-10 | Aurora Ev-Icd Mri Surescan | $175 |
| Bayer Healthcare Pharmaceuticals | Education · 2025-09-08 | Kerendia | $20 |
| Philips North America | Meals · 2025-08-12 | Ambulatory Monitoring & Diagnostics Undivided | $33 |
| Boston Scientific | Meals · 2025-08-07 | Watchman Flx | $34 |
| Boston Scientific | Meals · 2025-07-17 | Watchman Flx | $9 |
| Abbvie | Meals · 2025-07-17 | Rinvoq | $120 |
| Boston Scientific | Meals · 2025-06-05 | Watchman Flx | $9 |
| Philips North America | Meals · 2025-06-03 | Ambulatory Monitoring & Diagnostics Undivided | $26 |
| Boston Scientific | Meals · 2025-04-10 | Farapulse | $7 |
| Boston Scientific | Meals · 2025-03-20 | Farapulse | $6 |
| Philips North America | Meals · 2025-02-03 | Mcot | $24 |
| Boston Scientific | Meals · 2025-01-17 | Watchman Flx | $6 |
| Boston Scientific | Meals · 2025-01-16 | Watchman Flx | $32 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $657
| Boston Scientific | Axios | $177 | 6 payments
|
| Novartis Pharmaceuticals | Leqvio | $101 | 4 payments
|
| Philips North America | (5044) Mcot | $68 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $52 | 2 payments
|
| Lexicon Pharmaceuticals | None | $51 | 3 payments
|
| Pfizer | Eliquis | $48 | 2 payments
|
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $38 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $30 | 2 payments
|
| Heartflow | Ffrct | $23 | 1 payment
|
| Medtronic | Reveal Linq | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $17 | 1 payment
|
| United Therapeutics | Tyvaso | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $15 | 1 payment
|
2023: $2,573
| Abbott Laboratories | Mitraclip | $1,446 | 12 payments
|
| Boston Scientific | Watchman Access System | $167 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $140 | 8 payments
|
| Novartis Pharmaceuticals | Leqvio | $116 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $102 | 4 payments
|
| Actelion Pharmaceuticals US | Opsumit | $85 | 4 payments
|
| Impulse Dynamics (USA) | Optimizer | $82 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $81 | 5 payments
|
| Amgen | Repatha | $70 | 3 payments
|
| Medtronic | Reveal Linq | $41 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $38 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $29 | 2 payments
|
| Pfizer | Eliquis | $28 | 1 payment
|
| Lexicon Pharmaceuticals | Inpefa | $28 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $26 | 1 payment
|
| Chiesi USA | Cleviprex | $26 | 1 payment
|
| Cook Medical | Zilver Ptx | $19 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $17 | 1 payment
|
| Philips Electronics North America | (5044) Mcot | $17 | 1 payment
|
| Scpharmaceuticals | Furoscix | $14 | 1 payment
|
2022: $1,080
| Boston Scientific | Jetstream Sc | $179 | 11 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $137 | 8 payments
|
| Janssen Pharmaceuticals | Xarelto | $132 | 9 payments
|
| Abbott Laboratories | Mitraclip | $127 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $94 | 5 payments
|
| Sanofi-Aventis U.S. | Multaq | $74 | 3 payments
|
| Pfizer | Eliquis | $68 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $55 | 3 payments
|
| Amgen | Repatha | $53 | 3 payments
|
| Novo Nordisk | Ozempic | $49 | 3 payments
|
| Medtronic | Reveal Linq | $35 | 2 payments
|
| Resmed | Air 11 | $25 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $20 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
2021: $668
| Novartis Pharmaceuticals | Entresto | $104 | 6 payments
|
| Abbott Laboratories | Mitraclip System | $94 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $89 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $87 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $78 | 4 payments
|
| Amgen | Repatha | $59 | 4 payments
|
| Medtronic | Reveal Linq | $49 | 3 payments
|
| Boston Scientific | Lux Dx | $43 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $18 | 1 payment
|
| Novo Nordisk | Ozempic | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $14 | 1 payment
|
2020: $237
| Abbott Laboratories | Mitra Clip System | $69 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $47 | 3 payments
|
| Boston Scientific | Lux-Dx | $38 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $21 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $18 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $17 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $15 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $13 | 1 payment
|
2019: $1,573
| Boston Scientific | Watchman | $611 | 6 payments
|
| Sanofi-Aventis U.S. | Multaq | $184 | 10 payments
|
| Abbott Laboratories | Mitra Clip System | $147 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $131 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $77 | 5 payments
|
| AngioDynamics | None | $69 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $62 | 4 payments
|
| Amgen | Repatha | $57 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $56 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $49 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $39 | 3 payments
|
| Pfizer | Eliquis | $31 | 2 payments
|
| Astellas Pharma US | Lexiscan | $20 | 1 payment
|
| Amarin Pharma | Vascepa | $15 | 1 payment
|
| Chiesi USA | Kengreal | $13 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $11 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1114157484
- Licence
- CA C137215, TX P9302California C137215: Current · expires 2027-01-31Texas P9302: Canc Non-Renewal
- Group
- Adventist Health Physicians Network · Lodi Memorial Hospital Association Inc
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X); Student in a training program (390200000X)
- Mailing address
- 1801 E March Ln Ste D400, Stockton, CA, 95210
- NPI first listed
- 2009-07-21
- NPI last updated
- 2019-01-24
This is when the NPI record was last certified, not a medical board exam.